Everly Health
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | $500k | Seed | |
$2.5m | Seed | ||
$2.5m | Series A | ||
N/A | N/A | Series B | |
$50.0m | Series B | ||
$25.0m | Series C | ||
$175m Valuation: $1.3b | Series D | ||
$75.0m Valuation: $1.3b | Secondary | ||
Total Funding | €232m |
Related Content
Recent News about Everly Health
EditEverlywell operates in the health and wellness market, providing at-home health testing kits that allow consumers to collect samples such as blood, urine, and saliva from the comfort of their homes. The company serves a wide range of clients, including individuals seeking to monitor their health, employers, and healthcare providers. Everlywell's business model revolves around direct-to-consumer sales through its website, offering over 30 different tests that cover various health aspects such as food sensitivity, fertility, hormone levels, and COVID-19. The company generates revenue by selling these test kits and providing the subsequent lab analysis and physician-reviewed results. Additionally, Everlywell has expanded its offerings to enterprise customers, providing rapid COVID-19 antigen tests for workplaces, clinics, schools, and government offices. The company ensures compliance with FDA guidelines and emphasizes ease of use, quick turnaround times, and reliable results.
Keywords: at-home testing, health kits, blood tests, urine tests, saliva tests, food sensitivity, fertility tests, hormone testing, COVID-19 tests, enterprise solutions.